Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease.
Parkinson's disease (PD) is the second most common progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons. Detecting changes in gene expression in untreated de novo patients with PD is important for understanding disease pathogenesis and for identifying biomarkers for preclinical stage of PD. In this study we investigate ST13 gene expression in the peripheral blood of different groups of patients with neurological diseases using reverse transcription reaction and real-time polymerase chain reaction (PCR). Our results suggest that the expression levels of ST13 cannot serve as a biomarker for early stages of PD.
Shadrina
Maria I
MI
Institute of Molecular Genetics RAS, 2 Kurchatov Sq, Moscow 123182, Russia.
Filatova
Elena V
EV
Karabanov
Aleksey V
AV
Slominsky
Peter A
PA
Illarioshkin
Sergey N
SN
Ivanova-Smolenskaya
Irina A
IA
Limborska
Svetlana A
SA
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis; D002352:Carrier Proteins / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood*; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis* / Q000097:blood; D018832:Molecular Chaperones
D015415:Biomarkers; D002352:Carrier Proteins; D025521:Tumor Suppressor Proteins; C101119:ST13 protein, human; D018832:Molecular Chaperones